AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22379625
Drug: Specialist first-episode
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specialist first-episode treatment plus specialist early intervention for borderline personality
Trial: 22379625
Drug: Specialist first-episode
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specialist first-episode treatment alone
Trial: 18727459
Drug: High monounsaturated
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High monounsaturated fatty acid diabetes-specific supplement (49.95% calories from fats)
Trial: 18727459
Drug: Diabetes-specific supplement
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes-specific supplement (34% calories from fats)
Trial: 7163723
Drug: Flurazepam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurazepam (30 mg, nightly for 2 weeks)
Trial: 30696255
Drug: Nimesulide 100
RxNorm normalized name: nimesulide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 100 mg tablet
Trial: 23398716
Drug: 3D conformal
RxNorm normalized name: stannous fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3D conformal treatment planning
Trial: 20952427
Drug: Clonidine 2
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonidine 2 µg kg⁻¹ in bupivacaine 0.2%
Trial: 20952427
Drug: Morphine 30
RxNorm normalized name: ethylmorphine 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 30 µg kg⁻¹ in bupivacaine 0.2%
Trial: 19192106
Drug: Self-reported use
RxNorm normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-reported use of ED medications
Trial: 17374742
Drug: Intensified maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified maintenance chemotherapy (n = 89)
Trial: 15125746
Drug: Gemcitabine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine with radiotherapy (300 mg/m2/week)
Trial: 12397466
Drug: Quadramet (samarium‐153
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadramet (samarium‐153 EDTMP) at an average dose of 740 MBq in tracer studies and up to 50 GBq in therapy infusions.
Trial: 12397466
Drug: Quadramet (samarium‐153
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadramet (samarium‐153 EDTMP) at an average dose of 740 MBq in tracer studies.
Trial: 7661492
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (2.5 g of colestipol plus 2.5 g of psyllium)
Trial: 7661492
Drug: Colestipol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colestipol alone (5 g)
Trial: 7661492
Drug: Psyllium alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium alone (5 g)
Trial: 7661492
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 g cellulose)
Trial: 2034085
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy using large field radiotherapy (total irradiation of 20 Gy, daily fractionation of 4 Gy) and induced hyperglycemia (22‐23 mmol/l)
Trial: 2034085
Drug: Induced hyperglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induced hyperglycemia after discontinuation of radiotherapy sessions
Trial: 31658148
Drug: Prolonged dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged dual antiplatelet therapy (DAPT) (>12 months)
Trial: 30955096
Drug: Piezocision-assisted orthodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piezocision-assisted orthodontic treatment
Trial: 30991984
Drug: Conventional orthodontic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional orthodontic treatment
Trial: 28644196
Drug: Cebranopadol 200
RxNorm normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cebranopadol 200 μg once daily
Trial: 28644196
Drug: Cebranopadol 400
RxNorm normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cebranopadol 400 μg once daily
Trial: 28644196
Drug: Cebranopadol 600
RxNorm normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cebranopadol 600 μg once daily
Trial: 28644196
Drug: Tapentadol 200
RxNorm normalized name: tapentadol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tapentadol 200 mg twice daily
Trial: 28644196
Drug: Cebranopadol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cebranopadol (all doses)
Trial: 28644196
Drug: Cebranopadol (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cebranopadol (target doses)
Trial: 25775881
Drug: Low-concentration iodinated
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-concentration iodinated contrast medium (Iodixanol, 270 mg I/ml) with low tube voltage (80 kV)
Trial: 25775881
Drug: High-concentration iodinated
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration iodinated contrast medium (Iodixanol, 320 mg I/ml) with standard tube voltage (120 kV)
Trial: 25775881
Drug: Low-concentration iodinated
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-concentration iodinated contrast medium (Iodixanol, 270 mg I/ml)
Trial: 25775881
Drug: High-concentration iodinated
RxNorm normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-concentration iodinated contrast medium (Iodixanol, 320 mg I/ml)
Trial: 23069363
Drug: Time-based Green
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-based Green Prescription
Trial: 17323788
Drug: Ibuprofen sodium
RxNorm normalized name: Ibuprofen sodium
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen sodium dihydrate (256 mg sodium salt, equivalent to 200 mg ibuprofen)
Trial: 17323788
Drug: Ibuprofen acid
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen acid (200 mg ibuprofen)
Trial: 15143880
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant chemotherapy with biweekly administration of 1000 mg/m2 gemcitabine
Trial: 9537489
Drug: IgG CPS
RxNorm normalized name: methylcellulose (1500 CPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG CPS antibodies against serotypes Ia, II and III
Trial: 9537489
Drug: IgM antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgM antibodies against serotype III CPS
Trial: 8023538
Drug: Taprostene (T)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taprostene (T) at a continuous infusion of 25 ng/kg/min (in one case 12.5 ng/kg/min)
Trial: 2486180
Drug: Gentamicin serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin serum levels determined only if renal dysfunction evident or if patient failed to respond to therapy
Trial: 2486180
Drug: Gentamicin serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin serum levels determined after the third dose
Trial: 9428939
Drug: Community intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community intervention program including mass health education, nutrition education, antismoking propaganda, detection and treatment of hypertension, diabetes, and hyperlipidemia.
Trial: 8491161
Drug: Oily fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oily fish diet (170 g daily for 6 weeks)
Trial: 8491161
Drug: White fish
RxNorm normalized name: WHITE FISH
DrugBank: White fish (DB10627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White fish diet (170 g daily for 6 weeks)
Trial: 3326423
Drug: Droperidol (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (7.5 mg single dose)
Trial: 18262140
Drug: Transdermal Scopolamine
RxNorm normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal Scopolamine
Trial: 29223745
Drug: Buparlisib (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buparlisib (100 mg per day) plus fulvestrant (500 mg on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day cycles)
Trial: 29223745
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus fulvestrant (500 mg on days 1 and 15 of cycle 1 and on day 1 of subsequent 28-day cycles)
Trial: 24860968
Drug: New and
RxNorm normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 27 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 50 mg in 1 mL TOPICAL LOTION [Loreal Paris Age Perfect Rosy Tone SPF 30 Renew and revive healthy tone Visibly younger-looking skin]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New and existing pharmacological strategies for constipation treatment
Trial: 19038712
Drug: 24-hour pain
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24-hour pain pump with 0.375% ropivacaine infusion at a continuous rate of 5 mL/h
Trial: 19038712
Drug: 24-hour pain
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24-hour pain pump with 0.375% ropivacaine infusion
Trial: 8843991
Drug: Oral riboflavin
RxNorm normalized name: riboflavin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral riboflavin (20, 40, 60 mg)
Trial: 8843991
Drug: Oral riboflavin
RxNorm normalized name: riboflavin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral riboflavin (40 mg) in female patients with liver cirrhosis
Trial: 8843991
Drug: Oral riboflavin
RxNorm normalized name: riboflavin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral riboflavin (various doses)
Trial: 27296860
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance exercise for 15 weeks, twice per week.
Trial: 11783223
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy combined with Chinese herbal medicine (CHM)
Trial: 11783223
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy alone (Control)
Trial: 30590810
Drug: Group-delivered Acceptance
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-delivered Acceptance and Commitment Therapy (ACT)
Trial: 30590810
Drug: Group-delivered Cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-delivered Cognitive Behavioral Therapy (CBT)
Trial: 25142778
Drug: Laropiprant 100mg
DrugBank: Laropiprant (DB11629)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laropiprant 100mg once daily for 4 weeks
Trial: 16380237
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (quetiapine, olanzapine, risperidone, clozapine)
Trial: 16380237
Drug: Typical antipsychotics
RxNorm normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Typical antipsychotics (haloperidol, chlorpromazine)
Trial: 11443537
Drug: Interferon-alpha (IFN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN alpha) immunotherapy
Trial: 9769277
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 micrograms inhaled 15 min prior to L-ASA challenge)
Trial: 9769277
Drug: Placebo (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inhaled 15 min prior to L-ASA challenge)
Trial: 2826714
Drug: Cyclophosphamide, doxorubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide, doxorubicin, and cisplatin (CAP) followed by mitomycin, lomustine, and methotrexate (MCM) on progression (sequential)
Trial: 31416695
Drug: Pump On
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pump On (50% basal insulin at exercise onset)
Trial: 31416695
Drug: Pump Off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pump Off (0% basal insulin at exercise onset)
Trial: 25554993
Drug: Internet-based preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based preventive program adjunctive to usual pharmacological management
Trial: 25554993
Drug: Attention control
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Attention control treatment (directing subjects to healthy living websites)
Trial: 21978765
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus carboplatin (GC) - gemcitabine 1,000 mg/m² on days 1 and 8, plus carboplatin AUC 5 on day 1, every 21 days for up to six cycles.
Trial: 21978765
Drug: Paclitaxel plus
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel plus carboplatin (TC) - paclitaxel 175 mg/m² plus carboplatin AUC 6 on day 1, every 21 days for up to six cycles.
Trial: 21978765
Drug: Paclitaxel consolidation
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel consolidation therapy - 135 mg/m² every 28 days for ≤ 12 months, for patients with complete response (CR).
Trial: 21978765
Drug: Single-agent crossover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent crossover therapy for patients without CR, at induction doses/schedules until CR, disease progression (PD), or unacceptable toxicity.
Trial: 18547152
Drug: 1 cartridge
RxNorm normalized name: Product containing precisely somatropin 1 milligram/1 cartridge powder for conventional release solution for injection (clinical drug)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 cartridge phentolamine administered intravenously (1Piv)
Trial: 9124194
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and filgrastim (5 microg/kg/day s.c.)
Trial: 9124194
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and filgrastim (level 3: day 4 to day 7 and day 10 to day 13)
Trial: 9124194
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and filgrastim
Trial: 8438597
Drug: Daily supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily supplements of 26 ml water/kg body weight and 0.16 g sodium chloride/kg body weight during hypokinesia
Trial: 3462335
Drug: Oral melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral melatonin administration in 8 SAD patients
Trial: 3462335
Drug: Atenolol (beta-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta-adrenergic blocker) in 19 SAD patients
Trial: 15913898
Drug: Cognitive-behavioral coping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral coping skills therapy combined with pharmacotherapy
Trial: 10340838
Drug: 75 mg/day
RxNorm normalized name: Lyllana 0.075 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/day aspirin (n = 9399)
Trial: 21674768
Drug: Cefoperazone-sulbactam (CS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefoperazone-sulbactam (CS) 100 mg/kg/day
Trial: 21674768
Drug: Piperacillin-tazobactam (PIP/TAZO)
RxNorm normalized name: piperacillin / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin-tazobactam (PIP/TAZO) 360 mg/kg/day
Trial: 19358075
Drug: Local anaesthetics
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local anaesthetics injection
Trial: 3161813
Drug: 0.625 mg
RxNorm normalized name: estrone 0.625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.625 mg of conjugated estrogens (CE) daily
Trial: 3161813
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of intramuscular depomedroxyprogesterone acetate (DMPA) every 3 months
Trial: 28383836
Drug: Indacaterol/glycopyrronium 110/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indacaterol/glycopyrronium 110/50 μg (IND/GLY) once daily
Trial: 28383836
Drug: Salmeterol/proprionate of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/proprionate of fluticasone 50/500 μg (SAL/FC) twice daily
Trial: 25047458
Drug: edoxaban 15
RxNorm normalized name: edoxaban 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: edoxaban 15 mg once daily
Trial: 25047458
Drug: edoxaban 30
RxNorm normalized name: edoxaban 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: edoxaban 30 mg once daily
Trial: 25047458
Drug: enoxaparin 2000
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: enoxaparin 2000 IU (20 mg) twice daily
Trial: 22171728
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT), 6 sessions
Trial: 15889952
Drug: Oral quetiapine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral quetiapine
Trial: 18454611
Drug: Single music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single music therapy intervention
Trial: 12527977
Drug: 15-Pre (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15-Pre (75 g glucose dissolved in 500 ml water, ingested 15 min before exercise)
Trial: 12527977
Drug: 45-Pre (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45-Pre (75 g glucose dissolved in 500 ml water, ingested 45 min before exercise)
Trial: 12527977
Drug: 75-Pre (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75-Pre (75 g glucose dissolved in 500 ml water, ingested 75 min before exercise)
Trial: 10231449
Drug: L-arginine (17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (17 mg/kg/min over 30 min)
Trial: 27466218
Drug: Exenatide (EXE)
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide (EXE) twice daily (BID)
Trial: 31907737
Drug: Treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration
Trial: 23216646
Drug: NicVAX® co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NicVAX® co-administered with varenicline (Champix®)
Trial: 23216646
Drug: placebo co-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo co-administered with varenicline (Champix®)
Trial: 20405011
Drug: Directly observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly observed highly-active antiretroviral therapy (DOT)
Trial: 20405011
Drug: Self-administered HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered HAART
Trial: 18676757
Drug: ALVAC-CEA/B7.1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-CEA/B7.1 vaccine followed by chemotherapy (group 1)
Trial: 18676757
Drug: ALVAC-CEA/B7.1 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-CEA/B7.1 vaccine with tetanus toxoid adjuvant followed by chemotherapy (group 2)
Trial: 18676757
Drug: Chemotherapy followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy followed by ALVAC-CEA/B7.1 vaccine (group 3)
Trial: 8553592
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (all groups)
Trial: 18676757
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (group 3)
Trial: 15009104
Drug: Calcipotriol monotherapy
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol monotherapy
Trial: 15463842
Drug: Zafirlukast 20
RxNorm normalized name: zafirlukast 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zafirlukast 20 mg twice daily with routine treatment for four months
Trial: 10816408
Drug: Buscopan (hyoscine-N-butylbromide)
RxNorm normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buscopan (hyoscine-N-butylbromide) 20 mg administered before barium infusion (Group A)
Trial: 10816408
Drug: Buscopan (hyoscine-N-butylbromide)
RxNorm normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buscopan (hyoscine-N-butylbromide) 20 mg administered after barium infusion and gas insufflation (Group B)
Trial: 8666605
Drug: Preoperative irradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative irradiation (800 centigray dose)
Trial: 8666605
Drug: Postoperative irradiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative irradiation (800 centigray dose)
Trial: 1876282
Drug: Intravenous amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amino acid infusion (90 min)
Trial: 1876282
Drug: Intravenous amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous amino acid infusion (30 min)